Loading…
Rocket Pharmaceuticals, Inc. is projected to decline to $3.09 by 2027, a -1% move from its current price of $3.11. RCKT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $3.02 | $3.11 | $3.20 | 0.00% |
| Aug 4 | $2.99 | $3.11 | $3.24 | -0.01% |
| Aug 5 | $2.96 | $3.11 | $3.27 | -0.01% |
| Aug 6 | $2.94 | $3.11 | $3.29 | -0.01% |
| Aug 7 | $2.92 | $3.11 | $3.31 | -0.02% |
| Aug 8 | $2.90 | $3.11 | $3.33 | -0.02% |
| Aug 9 | $2.88 | $3.11 | $3.35 | -0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.88 | $3.11 | $3.35 | -0.02% |
| Week 2 | $2.79 | $3.11 | $3.46 | -0.05% |
| Week 3 | $2.73 | $3.11 | $3.54 | -0.07% |
| Week 4 | $2.67 | $3.11 | $3.61 | -0.10% |
| Week 5 | $2.62 | $3.11 | $3.68 | -0.12% |
| Week 6 | $2.58 | $3.11 | $3.74 | -0.15% |
| Week 7 | $2.54 | $3.10 | $3.79 | -0.17% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Rocket Pharmaceuticals, Inc. operates as a late-stage biotechnology company focusing on developing, manufacturing, and selling genetic therapies for rare and devastating diseases in the United States. Its programs include in vivo adeno-associated viral (AAV) therapies for Danon disease (RP-A501) in Phase 2, Plakophilin-2 Arrhythmogenic Cardiomyopathy (RP-A601) in Phase 1, and BAG3 Dilated Cardiomyopathy (BAG3-DCM) in preclinical development.
It also pursues ex vivo lentiviral (LV) programs for Leukocyte Adhesion Deficiency-I (RP-L201), Fanconi Anemia (RP-L102), and Pyruvate Kinase Deficiency (RP-L301). Rocket holds license agreements with multiple research institutions and universities. The company was founded in 1999 and is headquartered in Cranbury, New Jersey.
Rocket Pharmaceuticals, Inc. (RCKT) is currently priced at $3.14 per share and has a market cap of $342.87M, with a market rank of 3230. The near-term price path is reflected in the 30-day forecast, which shows neutral momentum through 2026–2029 before a bullish tilt emerges in 2030.
The multi-year forecast highlights rising averages and positive ROI beginning in 2030.
A major floor 24.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 36.3% above — a clean break opens room to run.
A major ceiling 50.8% above — clearing it would confirm fresh momentum.
Key RCKT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RCKT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.17 | Sell | $3.18 | Sell |
| MA 10 | $3.25 | Sell | $3.26 | Sell |
| MA 20 | $3.54 | Sell | $3.35 | Sell |
| MA 50 | $3.25 | Sell | $3.39 | Sell |
| MA 100 | $3.55 | Sell | $3.47 | Sell |
| MA 200 | $3.58 | Sell | $3.93 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.93 | Neutral |
| Stoch RSI (14) | 0.47 | Buy |
| CCI (20) | -90.74 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -14.79 | Sell |
| Bollinger %B (20,2) | 0.20 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.01 | Buy |
| Awesome (5,34) | -0.26 | Sell |
| Ultimate (7,14,28) | 27.84 | Buy |
| Momentum (10) | -0.33 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 3.12 | Sell |
| ADX (14) | 20.01 | Sell |
| ATR (14) | 0.09 | Info |
The 30-day technical picture shows bearish sentiment at present. RSI14 is 40, and the price remains below the SMA50 of $3.26 and the SMA200 of $3.59, signaling downside pressure near term. Support sits at $2.66 and resistance at $4.24, framing the immediate range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.60 | $3.11 | $3.74 | 0% | Neutral | |
| $2.46 | $3.09 | $4.12 | -1% | Neutral | |
| $2.34 | $3.04 | $4.21 | -2% | Neutral | |
| $2.44 | $3.24 | $4.63 | +4% | Neutral | |
| $2.93 | $3.98 | $5.82 | +28% | Bullish | |
| $3.02 | $4.19 | $6.27 | +35% | Bullish | |
| $3.05 | $4.31 | $6.58 | +38% | Bullish | |
| $3.13 | $4.49 | $6.99 | +44% | Bullish | |
| $3.04 | $4.44 | $7.02 | +43% | Bullish | |
| $3.01 | $4.46 | $7.16 | +43% | Bullish | |
| $4.13 | $6.56 | $11.23 | +111% | Bullish | |
| $5.90 | $10.62 | $19.94 | +241% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.60 | $3.11 | $3.65 | +0.00% |
| September 2026 | $2.54 | $3.01 | $3.67 | -3.18% |
| October 2026 | $2.60 | $3.10 | $3.82 | +2.95% |
| November 2026 | $2.58 | $3.10 | $3.85 | -0.09% |
| December 2026 | $2.47 | $2.98 | $3.74 | -3.68% |
Click any year to see its month-by-month RCKT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, RCKT is projected to trade between $2.60 and $3.74, averaging $3.11 — a potential gain of 0% from today's $3.11. A consolidation phase looks the most probable path here.
Rocket Pharmaceuticals, Inc.'s 2027 outlook centres on $3.09, within a $2.46 to $4.12 range. That is -1% versus the projected 2026 average. That marks a -1% change versus current levels. Price action looks broadly range-bound.
By 2028, RCKT could reach as high as $4.21, with a base case around $3.04 and support toward $2.34 — roughly -2% from $3.11. A consolidation phase looks the most probable path here.
Expect RCKT to range from $2.44 to $4.63 through 2029. The $3.24 average target implies a +4% move from current prices. That is up +7% on the projected 2028 average. Price action looks broadly range-bound.
The RCKT price prediction for 2030 points to an average of $3.98 (low $2.93, high $5.82) — a potential gain of +28% on today's $3.11. Buyers look set to stay in control over this stretch.
In 2031, RCKT is projected to trade between $3.02 and $6.27, averaging $4.19 — a potential gain of +35% from today's $3.11. That is up +5% on the projected 2030 average. Momentum favours further upside here.
Rocket Pharmaceuticals, Inc.'s 2032 outlook centres on $4.31, within a $3.05 to $6.58 range. That is up +3% on the projected 2031 average. That marks a +38% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, RCKT could reach as high as $6.99, with a base case around $4.49 and support toward $3.13 — roughly +44% from $3.11. Momentum favours further upside here.
Expect RCKT to range from $3.04 to $7.02 through 2034. The $4.44 average target implies a +43% move from current prices. That is -1% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The RCKT price prediction for 2035 points to an average of $4.46 (low $3.01, high $7.16) — a potential gain of +43% on today's $3.11. Momentum favours further upside here.
In 2040, RCKT is projected to trade between $4.13 and $11.23, averaging $6.56 — a potential gain of +111% from today's $3.11. That is up +47% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Rocket Pharmaceuticals, Inc.'s 2050 outlook centres on $10.62, within a $5.90 to $19.94 range. That is up +62% on the projected 2040 average. That marks a +241% change versus current levels. Momentum favours further upside here.
Investing $1,000 in RCKT today (≈ 321.543408 RCKT) could be worth
$3,414.45
+$2,414.45 (+241%) by 2050 · US Dollar
Based on the average projected RCKT price of $10.62 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RCKTwould be worth at today's price.
$1,000 invested in RCKT on Jul 31, 2025 (≈ 327.868858 RCKT) would be worth
$1,019.67
+$19.67 (+2.0%) today · 1.02× · US Dollar
Based on a RCKT entry price of $3.05 vs. today's $3.11.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.19 | $974.92 | -2.5% |
| 1 month ago | $3.52 | $883.52 | -11.6% |
| 3 months ago | $3.56 | $873.6 | -12.6% |
| 6 months ago | $3.48 | $893.68 | -10.6% |
| 1 year ago | $3.05 | $1,019.67 | +2.0% |
| All time (5.0y) ago | $35.96 | $86.48 | -91.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RCKT forecast.
Our base-case forecast reaches $6.20 around 2040.
Implied market cap at $6.20: $677M
The forecast turns bullish starting in 2030, with an average price of $3.96 and a 26% ROI. By 2040, the average is $6.39 with a 103.4% ROI, and by 2050 the average reaches $10.17 with a 223.9% ROI. The path includes years with neutral expectations (e.g., 2026–2029) and then a sustained bullish trend into the 2030s and beyond.
These are estimates, not guarantees, and depend on clinical progress, regulatory outcomes, and market dynamics.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $3.96, with a minimum of $2.87 and a maximum of $5.89, and a 26% ROI. Sentiment is bullish.
Forecasts show neutral sentiment through 2026–2029, with average prices around $3.14–$3.18, turning bullish in 2030 and improving to $3.96 (2030), $6.39 (2040), and $10.17 (2050), with ROIs of 26%, 103.4%, and 223.9% respectively.
The 2050 forecast lists an average price of $10.17 with a 223.9% ROI, indicating a path toward $10 for that year, though these are estimates and not guarantees.
Current price is $3.14 per share. Market cap is $342.87M, with a market rank of 3230.
RP-A501 Danon disease (Phase 2); RP-A601 PKP2-ACM (Phase 1); BAG3-DCM (preclinical); RP-L201 LAD-I; RP-L102 FA; RP-L301 PKD.
Rocket Pharmaceuticals, Inc. Community Discussion
0Share your Rocket Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.